ECCO 2023 Archives

La nutrition entérale exclusive est le gold standard pour induire la rémission au cours de la maladie de Crohn pédiatrique Luba Plotkin (Jerusalem, ISRAEL) - OP34 Enteral Nutrition Compared with Steroids in Children with Crohn’s Disease – In Israel: a nationwide study from the epi-IIRN
Ustekinumab vs anti-TNF dans la maladie de Crohn : Résultats à 2 ans de l’étude prospective observationnelle RUN-CD B. Bokemeyer, Allemagne. OP36 Real-world evidence on comparative effectiveness of Ustekinumab vs anti-TNF in Crohn’s disease with propensity score adjustment: two-year maintenance phase results from the prospective observational RUN-CD study
Peut-on arrêter les anti-TNF lors d’une combothérapie sans risque de récidive ? Maria Chaparro - Is the withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission feasible without increasing the risk of relapse? Results from the randomised clinical trial of GETECCU (EXIT)
L’Upacitinib dans la maladie de Crohn, effet de l’exposition à une biothérapie Laurent Peyrin-Biroulet - Endoscopic and clinical outcomes of upadacitinib in patients with moderately to severely active Crohn’s disease by number and type of prior biologics
Découverte de MICI lors d’examen de dépistage Eduard Brunet - Asymptomatic inflammatory bowel disease diagnosed during the colorectal cancer population screening in Catalonia
Les biothérapies n’augmentent pas le risque de complication post opératoire au cours de la maladie de Crohn Mathurin FUMERY (Amiens, FRANCE) - DOP 89 Impact of biologics on the risk of early postoperative complications in Crohn's disease: a French nationwide study
La chirurgie : une alternative aux anti-TNF au diagnostic de la maladie de Crohn iléocæcale ? Manasi Agrawal (Copenhagen, Danemark) - OP11 Ileocecal resection for recently diagnosed ileocecal Crohn’s disease is associated with improved longterm outcomes compared to anti-tumor necrosis factor therapy: a population-based study.
Pronostic à long-terme après une chirurgie précoce au cours de la maladie de Crohn Nathan Grellier (Paris) - DOP10 Early intestinal resection in Crohn’s Disease is not associated with severe long-term disease course
Le vedolizumab chez les patients avec pochite chronique Jairath Vipul - Mucosal healing with vedolizumab in inflammatory bowel disease patients with chronic pouchitis: Evidence from EARNEST, a randomized, double-blind, placebo-controlled trial
Etude de cohorte prospective sur 40 ans: incidence de la colectomie dans la RCH Peter.L. Lakatos PhD, Mcgill University Health Center, IBD Centre, Montréal, Canada, Long-term Colectomy rates of Ulcerative Colitis over 40-year of Different Therapeutic eras – Results from a Western Hungarian Population-based Inception Cohort between 1977–2020
Une consultation unique de transition pédiatrie adulte réduit le risque de poussée dans l’année Cristina Rubín De Célix (Alicante, Espagne) - OP27 Benefits of paediatric to adult transition program in Inflammatory Bowel Disease: The BUTTERFLY study of GETECCU
Contraception chez les femmes avec MICI aux US Erica Brenner - Contraceptive method use according to Inflammatory Bowel Disease status among young women in the United States
Résultats de l’étude REPREVIO : Le Vedolizumab prévient-il la récidive post opératoire dans la maladie de Crohn ? Geert D'Haens, Amsterdam University Medical Centres, Gastroenterology, Amsterdam, The Netherlands,Prevention of postoperative recurrence of Crohn's disease with vedolizumab: First results of the prospective placebo-controlled randomised trial REPREVIO
L’antibiothérapie, facteur de risque de MICI même chez l’adulte Adam Faye - Antibiotic Use as a Risk Factor for Inflammatory Bowel Disease Across the Ages: A PopulationBased Cohort Study
La rémission durable après résection iléocaecale dans la maladie de Crohn est-elle possible ? Résultats au long court de la cohorte du GETAID chirurgie S. Abdalla, Le Kremlin-Bicetre, France; DOP77Is durable remission achievable after ileocolic resection for Crohn's disease? Long-term results of a prospective multicentric cohort study of the GETAID Chirurgie
L’échographie dans la maladie de Crohn : outil validé ? Barbara Morao, Hospital Beatriz Ângelo, Gastroenterology, Lisbon, Portugal,Intestinal ultrasound correlates with colonoscopy and biomarkers, and can be used in a tight monitoring approach to assess response to therapy in Crohn's disease: a multicentre prospective study
Risque de complications néphrologiques et MICI Yuanhang Yang (Stockholm, Sweden) - OP07 Absolute and relative risks of kidney and urological complications in patients with Inflammatory Bowel Disease
Upadacitinib dans la RCH modérée à sévère : efficacité prouvée même après anti-TNF ! Séverine Vermeire, University Hospital Leuven, Department of Gastroenterology & Hepatology, Leuven, Belgium; Abstract citation ID: jjac190.0004, OP04, Efficacy of upadacitinib in ulcerative colitis: A phase 3 post hoc analysis of biologic- and anti- TNF-inadequate response patients